« Return to News | CROs/Service Providers

Etrials Restructuring—Again

Monday, December 22, 2008 11:13 AM

A month after naming a new permanent CEO, beleaguered eClinical company etrials is reorganizing its management structure—a move that will result in the departure of once-interim CEO Chuck Piccirillo as well as two other senior executives.

This is the second major management restructuring for etrials in 2008. Earlier this year, the company lost its CEO, chief financial officer, and chief operating officer (whose position was eliminated).

Piccirillo served as CEO from July to November while the company launched an executive search to replace Chip Jennings, who resigned suddenly in July. Piccirillo was replaced by permanent CEO M. Denis Connaghan in November and resumed his position as vice president of technology.

The reorganization, according to a company statement, is intended to better align operations with customer need and more effectively leverage strengths. However, the announcement comes after more than a year of financial struggle for the Morrisville, N.C.-based company.

In November, etrials reported a $6.1-million net loss for the third quarter. The company’s share prices have dropped almost 70% since the start of the year to $0.84 in morning trading.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.